low - Clinical-stage biotechs are largely insulated from GDP fluctuations as trial timelines and regulatory processes follow scientific rather than economic cycles. However, severe recessions can impact: (1) ability to raise capital as risk appetite contracts, (2) patient enrollment if economic stress affects trial participation, and (3) post-approval commercial uptake if payers tighten formulary access. The company's current 6.01x liquidity ratio provides buffer against near-term funding market volatility.

Rising interest rates create significant headwinds through multiple channels: (1) Valuation compression - clinical-stage biotechs are valued on discounted cash flows 5-10 years out, making them highly duration-sensitive (similar to long-dated bonds). A 100bp rate increase can compress biotech valuations 15-25%. (2) Financing costs - while Alumis has minimal debt (0.10 D/E), future capital raises become more expensive as investors demand higher returns. (3) Opportunity cost - higher risk-free rates make speculative biotech investments less attractive versus safer alternatives. The 376% three-month return suggests momentum-driven positioning that could reverse sharply if the Fed maintains restrictive policy.

growth/momentum - The 425% one-year return and 376% three-month surge indicate speculative momentum positioning by hedge funds and retail traders betting on positive Phase 3 catalysts. Typical investor base includes: (1) Specialized healthcare hedge funds with clinical trial expertise, (2) Venture capital crossover funds bridging private/public markets, (3) Retail momentum traders chasing biotech volatility, (4) Event-driven funds positioning ahead of binary data readouts. Minimal dividend/value investor presence given zero revenue and negative cash flow. Institutional ownership likely concentrated among funds with high risk tolerance and 3-5 year investment horizons.